Upcoming U.S. FDA Decision A Potentially Major De-Risk Event For Revive Therapeutics
It’s been a long and arduous road for Revive Therapeutics Ltd. (OTC: RVVTF) regarding their Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19.
Benzinga ·